Rentschler Biopharma and Vetter pursue the共同目标 to simplify processes and shorten time-to-market.

Vetter and Rentschler Biopharma, two globally operating service companies for biopharmaceuticals (Contract Development and Manufacturing Organization, CDMO), announced today their strategic collaboration to expand their services and offer complementary capabilities and expertise along the value chain. Biopharmaceutical companies face significant pressure when launching their products on the market, as drug development becomes increasingly complex and costly. The goal of the collaboration is to create long-term added value to enable customers to provide faster and easier product supply to their patients.

"We are pleased to collaborate with such a highly regarded and successful company. Vetter, like us, is a family-run, well-established service provider in the market. We have known each other for many years and both commit to high quality and sustainable value creation. Our collaboration aims to reduce complexity for our customers and thus enable patients with severe and rare diseases to access promising new therapies even faster," said Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma.

Senator h.c. Udo J. Vetter, Chairman of the Advisory Board of Vetter, added: "For companies, it is important to look ahead and drive forward future-oriented and innovative ideas. This is part of our two corporate strategies. The combination of Rentschler Biopharma's experience in active ingredient production and our own core competence in the manufacturing and packaging of pharmaceuticals is another way to pursue this path."

The two companies have already identified initial areas of activity with the goal of creating valuable added value for customers and their products through early and active exchange of know-how and best practice experiences. In the coming months, these opportunities will be further explored and deepened in pilot customer projects with joint teams from both companies.

"We are excited about collaborating with Vetter to complement our customer solutions, which are tailored even for the most complex biopharmaceuticals," said Dr. Frank Mathias, CEO of Rentschler Biopharma. "Vetter brings a wealth of experience in filling clinical and commercial drugs, from which our growing product pipeline can benefit. Their services fit perfectly with our own offerings. Our collaboration holds promise to further simplify customer solutions while expanding the boundaries of what is possible in biopharmaceutical production."

Peter Sölkner, Vetter CEO, agreed: "There are important synergies in the business portfolios of both companies that can be profitable for future markets and positively impact our customers' business and ultimately the treatment of their patients. By sharing our experiences, we aim to increase efficiency in drug development, explore new ways, and optimize supply chains so that companies can better meet the challenges of increasing complexity across the industry."

Both pharmaceutical service providers will continue to serve their existing and new customers independently. In today's rapidly evolving global healthcare environment, joint efforts are being made to develop integrated approaches for complex molecules.